Another class action lawsuit against GlaxoSmithKline and ZofranStaff writer ▼ | June 15, 2015
Bonsignore Trial Lawyers filed a complaint in Federal Court regarding GlaxoSmithKline's mislabeling and distribution of the drug Zofran.
Off-Label Morning sickness during their pregnancy
Zofran was originally approved by the Food and Drug Administration (FDA) to cure nausea in cancer patients undergoing chemotherapy. Without FDA approval and studies asserting the safety of the drug, GlaxoSmithKline fraudulently promoted the drug as a source of curing morning sickness in pregnant women.
The complaint alleges that GlaxoSmithKline endangered pregnant women by knowingly marketing Zofran "off label" as a safe and effective drug to cure morning sickness.
"GlaxoSmithKline's refusal to conduct studies and take the proper care to ensure the safety of the drug has caught up with the pharmaceutical giant. Recently, GlaxoSmithKline agreed to pay a $3 billion fine as a settlement," Bonsignore Trial Lawyers says.
In addition to prior settlements, the complaint cites numerous studies that have been conducted, supporting the contention that Zofran caused birth defects in children of pregnant women who took Zofran while pregnant. Many of the women affected by Zofran fairly allege that they were in no position to independently verify whether Zofran was a safe and effective method for treating pregnancy related nausea.
"At the end of the day, there existed an immensely disproportionate power between the victim and the pharmaceutical company. While GlaxoSmithKline could have easily verified the safety of the drug, the consumer had no way of verifying. As a result, GlaxoSmithKline not only took advantage of the consumer, but it also put pregnant women at risk.
"Through GlaxoSmithKline's knowing and willful acts to market an "off label" drug, it deceived hundreds of innocent women and their children and as the complaint alleges, the company acted in bad faith by failing to report related injuries that it did receive notice of," Bonsignore Trial Lawyers says. ■